Results 161 to 170 of about 360,596 (308)

Reframing Eczema: Th2-Skewed Contact Sensitization, Atopy Patch Testing, and Systemic Contact Dermatitis. [PDF]

Curr Allergy Asthma Rep
Jacob SE, Scheman A, Nedorost S.
europepmc   +1 more source

Paederus dermatitis

Indian Journal of Dermatology, 2014
Hai Err, Viroj Wiwanitkit
openaire   +3 more sources

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

Erythematous scaly plaques with erosions in a 4-month-old

JAAD Case Reports, 2022
Christine Y. Wong, MD, Anna A. Haggart, BS, Bernard Recht, MD, PhD   +2 more
doaj   +1 more source

High Curl Pattern Hair and Scalp Care Considerations to Mitigate Seborrheic Dermatitis. [PDF]

J Cosmet Dermatol
Callender V, Burgess C, Harvey VM, Heath C, Mitchell H, Woolery-Lloyd H, Andriessen A, McMichael A.   +7 more
europepmc   +1 more source

Mango dermatitis

Indian Journal of Dermatology, 2008
openaire   +3 more sources

Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Lebrikizumab is approved to treat patients with moderate‐to‐severe atopic dermatitis (AD). Objectives This study evaluated the 16‐week efficacy outcomes of lebrikizumab in adults and adolescents with severe AD in ADvocate trials who would be eligible for treatment based on South Korean reimbursement‐like criteria. Methods This was a
Chong Hyun Won, Chun Wook Park, Jiyoung Ahn, Joo Yeon Ko, Sang Hyun Cho, Yang Won Lee, Joo Hee Lee, Khai Jing Ng, Min Young Hong, Jinglin Zhong, Martin Dossenbach, Sang Wook Son   +11 more
wiley   +1 more source

Sociodemographic Disparities in Pediatric Dermatological Conditions: Insights From the 2019 Global Burden of Disease Project. [PDF]

Pediatr Discov
Mackenzie E, Dib N, Wolfe S, Rasty R, Sanabria B, Pai S.   +5 more
europepmc   +1 more source

Dermatitis Artefacta [PDF]

Proceedings of the Royal Society of Medicine, 1930
openaire   +5 more sources

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, EarlyView.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source